Inventiva SA
PAR:IVA

Watchlist Manager
Inventiva SA Logo
Inventiva SA
PAR:IVA
Watchlist
Price: 2.445 EUR 0.62% Market Closed
Market Cap: 212.5m EUR
Have any thoughts about
Inventiva SA?
Write Note

Inventiva SA
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Inventiva SA
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Inventiva SA
PAR:IVA
Cash from Financing Activities
€53.8m
CAGR 3-Years
-15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Cash from Financing Activities
€72.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanobiotix SA
PAR:NANO
Cash from Financing Activities
€46.3m
CAGR 3-Years
-24%
CAGR 5-Years
-4%
CAGR 10-Years
6%
G
Genfit SA
PAR:GNFT
Cash from Financing Activities
-€7.6m
CAGR 3-Years
44%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Cash from Financing Activities
-€23.5m
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
OSE Immunotherapeutics SA
PAR:OSE
Cash from Financing Activities
€8m
CAGR 3-Years
-27%
CAGR 5-Years
104%
CAGR 10-Years
N/A
No Stocks Found

Inventiva SA
Glance View

Market Cap
212.5m EUR
Industry
Biotechnology

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

IVA Intrinsic Value
5.226 EUR
Undervaluation 53%
Intrinsic Value
Price

See Also

What is Inventiva SA's Cash from Financing Activities?
Cash from Financing Activities
53.8m EUR

Based on the financial report for Jun 30, 2024, Inventiva SA's Cash from Financing Activities amounts to 53.8m EUR.

What is Inventiva SA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-15%

Over the last year, the Cash from Financing Activities growth was 154%. The average annual Cash from Financing Activities growth rates for Inventiva SA have been -15% over the past three years .

Back to Top